
ALC Stock Forecast & Price Target
ALC Analyst Ratings
Bulls say
Alcon is poised for a positive outlook as it anticipates enhanced top-line growth and solid operating margin expansion moving into FY26. The company's historical patterns suggest a potential boost in sales of Ocular Health products during the allergy season, with expectations for a strong performance of its Pataday brand in early 2026. Additionally, the introduction of new products is expected to drive higher-than-anticipated growth and market share gains, supporting the company's premium valuation through accelerating mid-teen EPS growth.
Bears say
Alcon faces a multitude of risks that may negatively impact its financial performance, including a potentially weaker economy that could hinder growth in over-the-counter (OTC) segments and delays in product rollouts. Furthermore, the company is experiencing increased competition and a weaker-than-expected uptake of new products, which are forecasted to contribute to growth rates falling below the anticipated range of 6% to 8%. Additionally, external factors such as China-based value-based pricing (VBP), tariffs, and foreign exchange headwinds may complicate margin expansion and overall market performance.
This aggregate rating is based on analysts' research of Alcon Inc. - Registered Shares and is not a guaranteed prediction by Public.com or investment advice.
ALC Analyst Forecast & Price Prediction
Start investing in ALC
Order type
Buy in
Order amount
Est. shares
0 shares